Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat and etoposide in relapsed/refractory neuroblastoma
NCT05338541Phase 1Recruiting
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucidinostat in neuroblastoma. Primary endpoint: Dose Limiting Toxicity at 1 year. Started May 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05338541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338541.